# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $13...
https://www.nature.com/articles/d41586-025-03093-6
JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $116 to $121.
- Reuters
- Reuters
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in h...
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump a...